Cargando…

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma

Patients with relapsed and/or refractory (R/R) follicular lymphoma (FL) and mantle cell lymphoma (MCL) have a poor prognosis with anticipated short progression-free and overall survivals. Two CD19-directed chimeric antigen receptor T-cell (CAR T) therapies are approved in the United States for R/R F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohty, Razan, Kharfan-Dabaja, Mohamed A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Recent Advances in Immunotherapy for Lymphoma and Multiple Myeloma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761215/ https://www.ncbi.nlm.nih.gov/pubmed/36544864 http://dx.doi.org/10.1177/20406207221142133

Ejemplares similares

Recent advances in immunotherapy for B-cell non-Hodgkin lymphoma and multiple myeloma
por: Chavez, Julio C., et al.
Publicado: (2022)

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
por: Albanyan, Omar, et al.
Publicado: (2022)

Current state of CAR-T therapy for T-cell malignancies
por: Luo, Liangkui, et al.
Publicado: (2022)

Prognostic and clinicopathological impacts of systemic immune-inflammation index on patients with diffuse large B-cell lymphoma: a meta-analysis
por: Fan, Zaijing, et al.
Publicado: (2023)

B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
por: Sanchez, Larysa, et al.
Publicado: (2021)

Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd)
por: Byun, Ja Min, et al.
Publicado: (2020)

The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era
por: Resende Salgado, Lucas, et al.
Publicado: (2018)

Case series: MRD negativity assessment using (11)C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma
por: Ngai, Cheong, et al.
Publicado: (2021)

MM-219: Outcome of COVID-19 Among Patients with Multiple Myeloma at the Armenian Hematology Center
por: Sahakyan, Lusine, et al.
Publicado: (2021)

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
por: Harush, Ortal, et al.
Publicado: (2022)

Follicular lymphoma
por: Leich, Ellen
Publicado: (2019)

Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation
por: Yang, Chen-lu, et al.
Publicado: (2021)

BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
por: Munoz, Javier L., et al.
Publicado: (2022)

BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis
por: Li, Guang, et al.
Publicado: (2020)

Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes
por: Mohty, Razan, et al.
Publicado: (2023)

Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy
por: Sheu, Tommy, et al.
Publicado: (2018)

Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
por: Beitinjaneh, Amer, et al.
Publicado: (2022)

Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphoma
por: Pinnix, Chelsea C., et al.
Publicado: (2018)

PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant
por: Thomas, Melissa, et al.
Publicado: (2023)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
por: Becnel, Melody R., et al.
Publicado: (2020)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites?
por: Lee, Jessica W., et al.
Publicado: (2019)

Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma
por: Bhangoo, Ronik S., et al.
Publicado: (2018)

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma
por: Usmani, Saad Z., et al.
Publicado: (2022)

Follicular lymphoma genomics
por: Kumar, Emil, et al.
Publicado: (2019)

CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
por: Chavez, Julio C., et al.
Publicado: (2019)

Intrafractional Displacement of Cardiac Substructures Among Patients With Mediastinal Lymphoma or Lung Cancer
por: Guzhva, Lidia, et al.
Publicado: (2019)

Does the Incidence of Treatment-Related Toxicity Plateau After Radiation Therapy: The Long-Term Impact of Integral Dose in Hodgkin's Lymphoma Survivors
por: Holtzman, Adam L., et al.
Publicado: (2019)

Immunotherapy beyond cellular therapy in follicular lymphoma: A case of complete remission after failure of two CAR‐T
por: Kase, Adam M., et al.
Publicado: (2022)

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
por: Li, Lingzhi, et al.
Publicado: (2022)

Poster: ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
por: Leslie, Lori A.
Publicado: (2021)

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
por: Zurko, Joanna, et al.
Publicado: (2022)

Controversies and Recent Advances in Hematopoietic Cell Transplantation for Follicular Non-Hodgkin Lymphoma
por: Kanate, Abraham S., et al.
Publicado: (2012)

Treatment of high-risk follicular lymphoma
por: Jurczak, Wojciech
Publicado: (2019)

EBV & lymphoma
por: Caballero, Dolores
Publicado: (2019)

Supportive Care for Patients with Lymphoma Undergoing CAR-T-cell Therapy: the Advanced Practice Provider’s Perspective
por: Granroth, Ginna, et al.
Publicado: (2022)

Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
por: Saifi, Omran, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_arnmdq1a8c3grrt8pvsmdb14b9